Krystal Biotech appoints Catherine Mazzacco to Board of Directors

Krystal Biotech, Inc.

Board expanded from 8 to 9 directors; Catherine Mazzacco appointed as independent Class I director effective March 6, 2023.
Mazzacco will serve on the Nominating and Corporate Governance committee and stand for election at 2024 annual meeting.
She previously served as CEO & President of LEO Pharma and SVP at GE HealthCare, with 25+ years at Abbott Laboratories.
No material transactions or arrangements between Mazzacco and the company; standard director compensation applies.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Catherine Mazzacco

independent member of the Board

KRYS · Krystal Biotech, Inc.

Effective: 2023-03-06
Filed: March 6, 2023, 6:59 PM ET

On March 6, 2023, the Board of Directors (the “Board”) of Krystal Biotech, Inc. (the “Company”) approved an increase in the size of the Board from eight (8) directors to nine (9) directors and appointed Catherine Mazzacco as an independent member of the Board to fill the vacancy created by the increase in the size of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Catherine Mazzacco was appointed as independent member of the Board at Krystal Biotech, Inc..

Action: appointed
Role: independent member of the Board

Exact text from the filing

On March 6, 2023, the Board of Directors (the “Board”) of Krystal Biotech, Inc. (the “Company”) approved an increase in the size of the Board from eight (8) directors to nine (9) directors and appointed Catherine Mazzacco as an independent member of the Board to fill the vacancy created by the increase in the size of the Board.

View on SEC.gov

Krystal Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001711279-23-000014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.